Loading...

Tesaro

DB:T8S
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
T8S
DB
$4B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. The last earnings update was 81 days ago. More info.


Add to Portfolio Compare Print
  • Tesaro has significant price volatility in the past 3 months.
T8S Share Price and Events
7 Day Returns
-0.7%
DB:T8S
1%
DE Biotechs
2.2%
DE Market
1 Year Returns
9.4%
DB:T8S
-21.7%
DE Biotechs
-18.8%
DE Market
T8S Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Tesaro (T8S) -0.7% 1.7% 109.2% 9.4% 87.4% 167.5%
DE Biotechs 1% 6.1% -2.6% -21.7% 36.2% -13.6%
DE Market 2.2% 4.6% -1.1% -18.8% 6.6% 7.1%
1 Year Return vs Industry and Market
  • T8S outperformed the Biotechs industry which returned -21.7% over the past year.
  • T8S outperformed the Market in Germany which returned -18.8% over the past year.
Price Volatility
T8S
Industry
5yr Volatility vs Market
Related Companies

T8S Value

 Is Tesaro undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Tesaro to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Tesaro.

DB:T8S Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 14 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 11.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:T8S
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 9.8%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.02
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.024 (1 + (1- 21%) (15.54%))
1.15
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.15
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.15 * 9.77%)
11.47%

Discounted Cash Flow Calculation for DB:T8S using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Tesaro is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:T8S DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) -408.00 -300.00 -31.00 188.00 494.00
Source Analyst x1 Analyst x1 Analyst x1 Analyst x1 Analyst x1
Present Value
Discounted (@ 11.47%)
-366.03 -241.45 -22.38 121.78 287.08
Present value of next 5 years cash flows $-221.00
DB:T8S DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $494.00 × (1 + 0.23%) ÷ (11.47% – 0.23%)
$4,405.65
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $4,405.65 ÷ (1 + 11.47%)5
$2,560.29
DB:T8S Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $-221.00 + $2,560.29
$2,339.29
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,339.29 / 55.23
$36.78
DB:T8S Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:T8S represents 0.86833x of NasdaqGS:TSRO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86833x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 42.35 x 0.86833
€36.78
Value per share (EUR) From above. €36.78
Current discount Discount to share price of €65.09
= -1 x (€65.09 - €36.78) / €36.78
-77%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Tesaro is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Tesaro's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Tesaro's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:T8S PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-11.86
NasdaqGS:TSRO Share Price ** NasdaqGS (2019-01-22) in USD $74.96
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 27.8x
Germany Market PE Ratio Median Figure of 418 Publicly-Listed Companies 17.55x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Tesaro.

DB:T8S PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:TSRO Share Price ÷ EPS (both in USD)

= 74.96 ÷ -11.86

-6.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tesaro is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Tesaro is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Tesaro's expected growth come at a high price?
Raw Data
DB:T8S PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts
40.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.75x
Germany Market PEG Ratio Median Figure of 276 Publicly-Listed Companies 1.37x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Tesaro, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Tesaro's assets?
Raw Data
DB:T8S PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $-2.38
NasdaqGS:TSRO Share Price * NasdaqGS (2019-01-22) in USD $74.96
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.44x
Germany Market PB Ratio Median Figure of 566 Publicly-Listed Companies 1.79x
DB:T8S PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:TSRO Share Price ÷ Book Value per Share (both in USD)

= 74.96 ÷ -2.38

-31.54x

* Primary Listing of Tesaro.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tesaro has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess Tesaro's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Tesaro has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

T8S Future Performance

 How is Tesaro expected to perform in the next 1 to 3 years based on estimates from 14 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Tesaro expected to grow at an attractive rate?
  • Tesaro's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Tesaro's earnings growth is expected to exceed the Germany market average.
  • Tesaro's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:T8S Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:T8S Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts 40.1%
DB:T8S Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 14 Analysts 29.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 9.9%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 19.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 9.9%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:T8S Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:T8S Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,052 332 201 7
2022-12-31 931 155 6 10
2021-12-31 664 -22 -234 10
2020-12-31 494 -73 -447 12
2019-12-31 349 -395 -557 14
2018-12-31 260 -480 -590 14
DB:T8S Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 219 -551 -649
2018-06-30 298 -415 -537
2018-03-31 270 -433 -522
2017-12-31 223 -400 -496
2017-09-30 180 -326 -450
2017-06-30 54 -427 -513
2017-03-31 61 -335 -420
2016-12-31 58 -288 -374
2016-09-30 53 -264 -314
2016-06-30 36 -220 -292
2016-03-31 1 -222 -294
2015-12-31 4 -195 -248

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Tesaro's earnings are expected to grow significantly at over 20% yearly.
  • Tesaro's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:T8S Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below

All data from Tesaro Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:T8S Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.46 6.37 -2.97 6.00
2022-12-31 -0.61 2.27 -5.47 7.00
2021-12-31 -3.33 -1.71 -5.86 7.00
2020-12-31 -6.42 -1.61 -9.91 10.00
2019-12-31 -9.27 -8.55 -10.86 12.00
2018-12-31 -10.76 -8.93 -11.37 13.00
DB:T8S Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -11.86
2018-06-30 -9.84
2018-03-31 -9.62
2017-12-31 -9.17
2017-09-30 -8.40
2017-06-30 -9.70
2017-03-31 -8.26
2016-12-31 -7.85
2016-09-30 -7.04
2016-06-30 -7.01
2016-03-31 -7.29
2015-12-31 -6.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Tesaro will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Tesaro's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Tesaro has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

T8S Past Performance

  How has Tesaro performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Tesaro's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Tesaro does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Tesaro's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Tesaro's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Tesaro's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Tesaro Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:T8S Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 219.37 -648.62 377.71 386.38
2018-06-30 297.74 -536.81 368.21 365.58
2018-03-31 270.00 -522.22 361.15 339.38
2017-12-31 223.33 -496.13 336.81 308.74
2017-09-30 180.22 -450.30 300.77 282.42
2017-06-30 54.45 -512.87 254.45 269.82
2017-03-31 60.79 -419.97 197.69 248.56
2016-12-31 58.02 -374.22 158.58 235.14
2016-09-30 53.33 -313.74 131.96 206.48
2016-06-30 36.43 -292.48 117.04 185.76
2016-03-31 0.62 -293.88 97.61 174.55
2015-12-31 4.04 -247.75 78.70 155.39
2015-09-30 0.09 -223.58 58.19 142.35
2015-06-30 -193.22 41.69 132.21
2015-03-31 -169.72 30.49 123.85
2014-12-31 -171.01 23.94 118.43
2014-09-30 -146.42 21.00 107.49
2014-06-30 -138.78 19.24 99.73
2014-03-31 -123.29 17.07 87.34
2013-12-31 -92.36 14.78 75.73
2013-09-30 -87.72 12.41 72.49
2013-06-30 -72.69 9.64 62.20
2013-03-31 -71.30 7.92 55.55
2012-12-31 -61.76 6.72 47.20
2012-09-30 -52.14 5.71 39.56
2012-06-30 -41.39 4.87 29.60
2012-03-31 -23.21 3.73 19.53

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Tesaro has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Tesaro has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Tesaro improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Tesaro's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Tesaro has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

T8S Health

 How is Tesaro's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Tesaro's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Tesaro is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Tesaro's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Tesaro's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Tesaro has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Tesaro Company Filings, last reported 3 months ago.

DB:T8S Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 -130.79 643.58 476.81
2018-06-30 -21.55 639.92 575.10
2018-03-31 117.73 440.42 498.98
2017-12-31 249.09 437.11 643.10
2017-09-30 407.36 140.36 521.27
2017-06-30 399.91 137.45 507.94
2017-03-31 513.21 134.53 672.24
2016-12-31 628.12 131.78 785.88
2016-09-30 502.22 129.02 647.32
2016-06-30 169.31 126.41 320.20
2016-03-31 160.96 123.80 314.46
2015-12-31 86.87 121.33 230.15
2015-09-30 149.94 121.86 302.52
2015-06-30 207.72 119.69 354.37
2015-03-31 262.12 117.51 399.15
2014-12-31 124.06 111.96 256.86
2014-09-30 168.12 113.43 295.91
2014-06-30 137.13 0.00 151.09
2014-03-31 170.61 0.00 180.29
2013-12-31 123.15 0.00 130.31
2013-09-30 143.73 0.00 156.44
2013-06-30 169.06 0.00 178.09
2013-03-31 188.92 0.00 198.64
2012-12-31 115.66 0.00 125.45
2012-09-30 133.54 0.00 138.58
2012-06-30 141.33 0.00 68.88
2012-03-31 88.51 0.00 88.64
  • Tesaro has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Tesaro's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Tesaro has sufficient cash runway for 1.4 years based on current free cash flow.
  • Tesaro has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 35.5% each year.
X
Financial health checks
We assess Tesaro's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Tesaro has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

T8S Dividends

 What is Tesaro's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Tesaro dividends.
If you bought €2,000 of Tesaro shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Tesaro's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Tesaro's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:T8S Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 329 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:T8S Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Tesaro has not reported any payouts.
  • Unable to verify if Tesaro's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Tesaro's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Tesaro has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Tesaro's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Tesaro afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Tesaro has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

T8S Management

 What is the CEO of Tesaro's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Lonnie Moulder
COMPENSATION $6,043,422
AGE 61
TENURE AS CEO 8.8 years
CEO Bio

Mr. Leon O. Moulder, Jr., also known as Lonnie, M.B.A., Co-founded TESARO, Inc. in March 2010 and has been Chief Executive Officer and Director since March 2010. Mr. Moulder served as the Chief Executive Officer and President of Abraxis BioScience Inc. at Abraxis Health, Inc. from April 30, 2009 to January, 2010. Mr. Moulder served as the Chief Executive Officer and President of MGI Pharma, Inc. from May 14, 2002 to January 2008 and May 13, 2003 to January 2008, respectively. He served as an Executive Vice President of MGI Pharma, Inc., from September 1999 to January 2008 and also served as its Chief Operating Officer from May 14, 2002 to January 2008. From October 1997 to September 1999, he served as a Vice President of Business Development & Commercial Affairs and a Member of the initial management team at Eligix Inc., a developmental stage biomedical company focused on developing therapies for cancer, infectious disease and auto-immune diseases, located in Boston. He has 16 years in various sales, marketing and business development positions with Hoechst Marion Roussel (now Aventis AG) and its predecessor companies, Marion Laboratories and Marion Merrell Dow Pharmaceuticals Inc., since September 1981. Mr. Moulder's tenure at Hoechst Marion Roussel (HMR) culminated as Product Group Director of Oncology and Anti-Infective Products. He began his career as a Clinical Pharmacist. He has been the Independent Chairman at Trevena, Inc. since June 2013. He served as a Vice Chairman of Abraxis BioScience, Inc. at Abraxis Health, Inc. from April 30, 2009 to January, 2010. He has sixteen years of commercial management experience beginning with Marion Laboratories and ultimately advancing through various management positions at successor companies, Marion Merrel Dow and Hoechst Marion Roussel. He served as Vice Chairman of Eisai Corporation of North America following Eisai's acquisition of MGI PHARMA Inc. from January 2008 to January 2009. He has been an Independent Director at Trevena, Inc. since November 2011. He served as a Director of LifeScience Alley. He serves as a Member of the Board of Visitors of the Temple University school of Pharmacy. He served as a Director of Cubist Pharmaceuticals Inc. from February 2010 to January 2015. He served as a Director of Abraxis BioScience Inc. until January 2010 and MGI Pharma Inc., from May 2003 to January 2008. He served as Director of Boston Healthcare and Biotechnology Industry Organization (BIO). He served as Director of Methylgene Inc. from 2004 to May 17, 2006. He serves on the board of the Fox Chase Cancer Center. He has a Bachelor of Science Degree in Pharmacy from Temple University and a Master of Business Administration degree from the University of Chicago.

CEO Compensation
  • Lonnie's compensation has increased whilst company is loss making.
  • Lonnie's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Tesaro management team in years:

3.8
Average Tenure
51
Average Age
  • The tenure for the Tesaro management team is about average.
Management Team

Lonnie Moulder

TITLE
Co-Founder
COMPENSATION
$6M
AGE
61
TENURE
8.8 yrs

Mary Hedley

TITLE
Co-Founder
COMPENSATION
$5M
AGE
55
TENURE
8.8 yrs

Tim Pearson

TITLE
Executive VP & CFO
COMPENSATION
$3M
AGE
50
TENURE
4.7 yrs

Martin Huber

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$3M
AGE
58
TENURE
3.3 yrs

Orlando Oliveira

TITLE
Senior VP & GM of International
COMPENSATION
$3M
AGE
42
TENURE
3.3 yrs

Bill Aitchison

TITLE
Senior Vice President of Technical Operations
TENURE
0.7 yrs

Jennifer Davis

TITLE
Vice President of Corporate Communications & Investor Relations

Joseph Farmer

TITLE
Senior VP
AGE
46
TENURE
3.8 yrs

Rebecca Mehrwerth

TITLE
Vice President of Sales
TENURE
4.3 yrs

Michelle Graham

TITLE
Senior VP & Chief Human Resources Officer
AGE
51
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Tesaro board of directors in years:

6.3
Average Tenure
61
Average Age
  • The tenure for the Tesaro board of directors is about average.
Board of Directors

Dave Mott

TITLE
Chairman
COMPENSATION
$1M
AGE
53
TENURE
7.5 yrs

Lonnie Moulder

TITLE
Co-Founder
COMPENSATION
$6M
AGE
61
TENURE
8.8 yrs

Mary Hedley

TITLE
Co-Founder
COMPENSATION
$5M
AGE
55
TENURE
8.8 yrs

Larry Alleva

TITLE
Independent Director
COMPENSATION
$1M
AGE
68
TENURE
6.8 yrs

Duke Collier

TITLE
Independent Director
COMPENSATION
$1M
AGE
71
TENURE
4.7 yrs

Beth Seidenberg

TITLE
Independent Director
COMPENSATION
$1M
AGE
61
TENURE
7.6 yrs

James Armitage

TITLE
Independent Director
COMPENSATION
$1M
AGE
71
TENURE
5.7 yrs

Garry Nicholson

TITLE
Independent Director
COMPENSATION
$1M
AGE
63
TENURE
3.7 yrs

Kavita Patel

TITLE
Independent Director
COMPENSATION
$1M
AGE
44
TENURE
2.8 yrs

Pascale Witz

TITLE
Director
AGE
51
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Mar 18 Sell Orlando Oliveira Individual 08. Mar 18 08. Mar 18 -3,000 €56.67 €-169,997
07. Mar 18 Buy New Enterprise Associates Company 02. Mar 18 06. Mar 18 145,532 €48.19 €6,730,966
05. Mar 18 Buy Leon Moulder Individual 02. Mar 18 02. Mar 18 5,000 €46.40 €231,156
X
Management checks
We assess Tesaro's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Tesaro has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

T8S News

Simply Wall St News

T8S Company Info

Map
Description

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Details
Name: Tesaro, Inc.
T8S
Exchange: DB
Founded: 2010
$3,644,581,252
55,231,566
Website: http://www.tesarobio.com
Address: Tesaro, Inc.
1000 Winter Street,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS TSRO Common Stock Nasdaq Global Select US USD 28. Jun 2012
DB T8S Common Stock Deutsche Boerse AG DE EUR 28. Jun 2012
LSE 0LEP Common Stock London Stock Exchange GB USD 28. Jun 2012
Number of employees
Current staff
Staff numbers
715
Tesaro employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/22 21:43
End of day share price update: 2019/01/22 00:00
Last estimates confirmation: 2019/01/18
Last earnings filing: 2018/11/02
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.